Bayer
FDA Approves Nubeqa to Treat Prostate Cancer
Bayer's Nubeqa was approved for the treatment of patients with nonmetastatic castration-resistant prostate ...
AUGUST 1, 2019
ZappRx and Bayer Partner to Improve Access to Specialty Medications
ZappRx and Bayer announced an agreement to provide a more efficient approach to accessing specialty medications and ...
JANUARY 24, 2019
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
FDA Approves Vitrakvi for Solid Tumors With NTRK Gene Fusions
Larotrectinib is indicated for tumors that have a NTRK gene fusion without a known acquired resistance mutation, ...
NOVEMBER 28, 2018
FDA Approves New Indication for Lenvima for HCC
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 17, 2018
FDA Grants Opdivo New Indication for HCC Patients Previously Treated With Sorafenib
The U.S. burden of hepatocellular carcinoma is significant. A recent ACS report noted that death rates from liver ...
OCTOBER 2, 2017